PDSB
PDS Biotechnology Corporation
$1.08
+$0.03(+2.86%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$48.97M
Volume
371.39K
52W Range
$0.85 - $4.29
Target Price
$7.50
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-39.5M | $-52.0M | $-3.6M | $17.1M | $14.9M | $21.4M | $41.7M | $43.0M | $36.3M | ||
| Research & Development | $24.8M | $34.3M | $830.7K | $6.1M | $7.9M | $11.3M | $29.4M | $27.8M | $22.6M | ||
| Research Expense | $24.8M | $34.3M | $830.7K | $6.1M | $7.9M | $11.3M | $29.4M | $27.8M | $22.6M | ||
| Selling, General & Administrative | $14.7M | $17.7M | $2.8M | $11.0M | $7.0M | $10.2M | $12.2M | $15.3M | $13.8M | ||
| General & Administrative Expenses | $14.7M | $17.7M | $2.8M | $11.0M | $7.0M | $10.2M | $12.2M | $15.3M | $13.8M | ||
| Salaries & Wages | $-5.3M | $-6.2M | $-251.9K | $-3.1M | -- | -- | -- | $7.6M | $6.8M | ||
| Depreciation & Amortization | -- | -- | $27.4K | $-98.4K | $15.6K | $5.4K | $86 | $17.4K | $21.1K | ||
| Depreciation & Amortization | -- | -- | $27.4K | $-98.4K | $15.6K | $5.4K | $86 | $17.4K | $21.1K | ||
| Amortization | -- | -- | -- | -- | $3.0M | -- | $183.9K | $652.0K | $1.2M | ||
| Other Operating Expenses | $-39.5M | $-52.0M | $-3.6M | $-21.0M | $183.4K | $185.2K | $232.5K | $43.0M | $36.3M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-39.5M | $-52.0M | $-3.6M | $-17.1M | $-14.9M | $-21.4M | $-41.7M | $-43.0M | $-36.3M | ||
| EBITDA | $-39.2M | $-50.9M | $-3.8M | $-7.2M | $-14.9M | $-21.4M | $-40.7M | $-39.3M | $-32.6M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | $1.2M | $2.2M | $3.6K | $33.6K | -- | -- | $1.3M | $4.2M | $4.7M | ||
| Intinc | -- | -- | $-190.3K | $353.5K | $55.0K | $4.3K | $935.2K | $2.9M | $2.5M | ||
| Net Non-Operating Interest Income/Expense | $-1.2M | $-2.2M | $-3.6K | $319.9K | $55.0K | $4.3K | $-381.3K | $2.9M | $2.5M | ||
| Gain on Sale of Securities | $212.3K | $700.9K | $871.9K | $-979.3K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-48.8K | $-700.9K | $186.7K | $-9.4M | $3.0M | -- | -- | -- | -- | ||
| Other Special Charges | $-163.5K | -- | $-186.7K | $81.7K | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | -- | -- | $44.7M | $31.1M | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | -- | $-44.7M | $-31.1M | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | $2.8M | $3.0M | $3.0M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-39.5M | $-51.3M | $-3.8M | $-7.3M | $-14.9M | $-21.4M | $-40.7M | $-40.2M | $-33.9M | ||
| Pre-Tax Income | $-40.7M | $-53.4M | $-3.8M | $-7.4M | $-14.8M | $-21.4M | $-42.1M | $-44.3M | $-38.5M | ||
| INCOME TAX | |||||||||||
| Tax Provision | $-1.8M | $-2.6M | $-2.8M | $-381.5K | -- | $-4.5M | $-1.2M | $-1.4M | $-900.0K | ||
| NET INCOME | |||||||||||
| Net Income | $-38.8M | $-50.9M | $-3.8M | $-7.0M | $-14.8M | $-16.9M | $-40.9M | $-42.9M | $-37.6M | ||
| Net Income (Continuing Operations) | $-38.8M | $-50.9M | $-3.8M | $-7.0M | $-14.8M | $-16.9M | $-40.9M | $-42.9M | $-37.6M | ||
| Net Income (Discontinued Operations) | $-38.8M | $-50.9M | $-3.8M | $-7.0M | $-14.8M | $-16.9M | $-40.9M | $-42.9M | $-37.6M | ||
| Net Income (Common Stockholders) | $-38.8M | $-50.9M | $-3.8M | $-7.0M | $-14.8M | $-16.9M | $-40.9M | $-42.9M | $-37.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-26.0M | -- | -- | $-39.4M | ||
| TOTALS | |||||||||||
| Total Expenses | $-39.5M | $-52.0M | $-3.6M | $17.1M | $14.9M | $21.4M | $41.7M | $43.0M | $36.3M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $1.4M | $1.5M | $1.6M | $4.9M | $16.7M | $25.6M | $28.6M | $31.0M | $36.5M | ||
| Average Shares Outstanding (Diluted) | -- | -- | -- | $4.9M | $16.7M | $25.6M | $28.6M | $31.0M | $36.5M | ||
| Shares Outstanding | $1.5M | $1.5M | $1.6M | $15.3M | $22.3M | $28.4M | $46.6M | $36.7M | $45.4M | ||
| Basic EPS | -- | -- | -- | $-6.4 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | ||
| Diluted EPS | -- | -- | -- | $1.44 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $1.44 | -- | $-0.66 | $-1.43 | $-1.39 | $-1.03 | ||
| OTHER METRICS | |||||||||||
| Gain On Sale Of P P E | -- | -- | -- | $-311.0K | -- | -- | -- | -- | -- | ||
| Other Gand A | $14.7M | $17.7M | $2.8M | $11.0M | $7.0M | $10.2M | $12.2M | $15.3M | $13.8M | ||
| Rent And Landing Fees | $14.7M | $17.7M | $2.8M | $-113.0K | $183.4K | -- | -- | -- | -- | ||
| Restruct | -- | -- | $44.7M | $31.1M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PDSB | $1.08 | +2.9% | 371.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get PDS Biotechnology Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW